혈액형 판정 시장 규모, 점유율, 성장 및 세계 산업 분석 : 종류별, 용도별, 지역별 인사이트와 예측(2026-2034년)

Growth Factors of blood group typing Market

The global blood group typing market plays a critical role in modern healthcare, supporting blood transfusions, organ transplantation, trauma care, and prenatal testing. According to Fortunebusinessinsights, the market was valued at USD 2.31 billion in 2025 and is projected to grow from USD 2.52 billion in 2026 to USD 5.27 billion by 2034, registering a CAGR of 9.60% during 2026-2034. The strong growth trajectory is driven by rising blood donations, increasing trauma cases, and expanding transplantation procedures worldwide.

Market Dynamics and Epidemiological Drivers

Blood group typing determines compatibility between donors and recipients, making it indispensable in emergency medicine and surgical care. The rising incidence of accidents and trauma cases has significantly increased the need for massive blood transfusions. Studies indicate that 6 out of 10 trauma-related deaths occur within the first three hours due to excessive bleeding, highlighting the critical role of timely blood typing.

Additionally, the World Health Organization (WHO) reported a rise of 10.7 million voluntary blood donations between 2008 and 2018, directly increasing the volume of blood group typing procedures. The growing burden of chronic diseases, rising surgical volumes, and expanding prenatal screening programs further support market expansion.

Market Impact of COVID-19

The COVID-19 pandemic temporarily disrupted the blood group typing market due to reduced blood donations, supply chain interruptions, and fewer hospital visits. In FY 2020, key players such as Bio-Rad Laboratories, Inc. reported a 7.6% decline in revenues from clinical diagnostics segments. However, market recovery was observed in 2021 and 2022, supported by improved patient inflow and accelerated adoption of automated blood typing technologies, restoring the market's growth momentum.

Key Market Trends

A major trend shaping the market is the adoption of automated blood group typing technologies, including PCR-based and microarray systems. These technologies improve testing accuracy, reduce human errors, and address shortages of skilled healthcare professionals. For example, in July 2020, scientists from Tokyo University of Science, Japan, developed a lab-on-a-chip device capable of determining blood type within five minutes, marking a significant technological advancement.

Market Segmentation Analysis

By Product, reagents and kits dominated the market, accounting for 80.43% share in 2026, due to their extensive use in transfusion and donation procedures. Instruments are expected to grow steadily with increased automation.

By Test Type, antibody screening led the market with a 39.80% share in 2026, driven by growing prenatal testing and chronic disease prevalence. ABO testing followed, while HLA typing and cross-matching tests are gaining traction due to rising organ transplantation procedures.

By Technique, serology tests held the largest share at 59.42% in 2026, owing to ease of use and widespread availability. Molecular tests are projected to grow faster due to their ability to detect weak antigen variants and improve transfusion safety.

By End User, independent laboratories and blood banks dominated with a 59.42% share in 2026, supported by expanding laboratory networks, particularly in emerging economies.

Regional Insights

North America dominated the global market with a 34.70% share in 2025, reaching USD 0.8 billion, driven by strong reimbursement policies and high transfusion demand. The U.S. market is projected to reach USD 0.81 billion by 2026.

Europe ranked second, supported by increasing transfusion volumes and government-led organ donation initiatives.

Asia Pacific is expected to witness strong growth due to rising R&D investments, with China, Japan, and India showing notable expansion by 2026.

Latin America and the Middle East & Africa are emerging markets, supported by improving healthcare infrastructure and growing awareness of blood donations.

Competitive Landscape

The market is semi-consolidated, led by QuidelOrtho Corporation, followed by Grifols S.A. and Bio-Rad Laboratories, Inc. These players focus on product innovation, strategic partnerships, and geographic expansion. Recent launches such as automated analyzers and next-generation HLA typing tests continue to strengthen competition.

Conclusion

In conclusion, the global blood group typing market is set for robust growth from USD 2.31 billion in 2025 to USD 5.27 billion by 2034, driven by increasing blood donations, trauma cases, and transplantation procedures. Technological advancements, especially in automated and molecular testing, are transforming diagnostic efficiency and safety. While infrastructure gaps in emerging countries remain a challenge, sustained government initiatives and private-sector innovation are expected to strengthen market penetration. Overall, the market presents strong long-term growth opportunities across both developed and developing regions.

Segmentation By Product

• Instruments
• Reagents & Kits

By Test Type

• ABO Tests
• Antigen Typing
• Antibody Screening
• Cross-matching Tests
• HLA Typing

By Technique

• Serology Tests
• Molecular Tests

By End-user

• Hospital-based Laboratories
• Independent Laboratories & Blood Banks

By Region

• North America (By Product, By Test Type, By Technique, By End-user, and By Country)
  • U.S.
  • Canada
• Europe (By Product, By Test Type, By Technique, By End-user, and By Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product, By Test Type, By Technique, By End-user, and By Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product, By Test Type, By Technique, By End-user, and By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, By Test Type, By Technique, By End-user, and By Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in Blood Group Typing Techniques
• 4.2. Number of Blood Donations, For Key Countries
• 4.3. Number of Blood Transfusions, For Key Countries/ Region
• 4.4. Key Industry Developments: Mergers, Partnership, Acquisitions
• 4.5. Brief Overview of Other Companies Operating in HLA Typing Products
• 4.6. Pricing Analysis of HLA Typing Products
• 4.7. Impact of COVID-19 on Blood Group Typing Market

5. Global Blood Group Typing Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Instruments
  • 5.1.2. Reagents & Kits
• 5.2. Market Analysis, Insights and Forecast - By Test Type
  • 5.2.1. ABO Tests
  • 5.2.2. Antigen Typing
  • 5.2.3. Antibody Screening
  • 5.2.4. Cross-matching Tests
  • 5.2.5. HLA Typing
• 5.3. Market Analysis, Insights and Forecast - By Techniques
  • 5.3.1. Serology Tests
  • 5.3.2. Molecular Tests
• 5.4. Market Analysis, Insights and Forecast - By End-user
  • 5.4.1. Hospital-based Laboratories
  • 5.4.2. Independent Laboratories & Blood Banks
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Blood Group Typing Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Instruments
  • 6.1.2. Reagents & Kits
• 6.2. Market Analysis, Insights and Forecast - By Test Type
  • 6.2.1. ABO Tests
  • 6.2.2. Antigen Typing
  • 6.2.3. Antibody Screening
  • 6.2.4. Cross-matching Tests
  • 6.2.5. HLA Typing
• 6.3. Market Analysis, Insights and Forecast - By Techniques
  • 6.3.1. Serology Tests
  • 6.3.2. Molecular Tests
• 6.4. Market Analysis, Insights and Forecast - By End-user
  • 6.4.1. Hospital-based Laboratories
  • 6.4.2. Independent Laboratories & Blood Banks
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Blood Group Typing Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Instruments
  • 7.1.2. Reagents & Kits
• 7.2. Market Analysis, Insights and Forecast - By Test Type
  • 7.2.1. ABO Tests
  • 7.2.2. Antigen Typing
  • 7.2.3. Antibody Screening
  • 7.2.4. Cross-matching Tests
  • 7.2.5. HLA Typing
• 7.3. Market Analysis, Insights and Forecast - By Techniques
  • 7.3.1. Serology Tests
  • 7.3.2. Molecular Tests
• 7.4. Market Analysis, Insights and Forecast - By End-user
  • 7.4.1. Hospital-based Laboratories
  • 7.4.2. Independent Laboratories & Blood Banks
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Blood Group Typing Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Instruments
  • 8.1.2. Reagents & Kits
• 8.2. Market Analysis, Insights and Forecast - By Test Type
  • 8.2.1. ABO Tests
  • 8.2.2. Antigen Typing
  • 8.2.3. Antibody Screening
  • 8.2.4. Cross-matching Tests
  • 8.2.5. HLA Typing
• 8.3. Market Analysis, Insights and Forecast - By Techniques
  • 8.3.1. Serology Tests
  • 8.3.2. Molecular Tests
• 8.4. Market Analysis, Insights and Forecast - By End-user
  • 8.4.1. Hospital-based Laboratories
  • 8.4.2. Independent Laboratories & Blood Banks
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Blood Group Typing Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Instruments
  • 9.1.2. Reagents & Kits
• 9.2. Market Analysis, Insights and Forecast - By Test Type
  • 9.2.1. ABO Tests
  • 9.2.2. Antigen Typing
  • 9.2.3. Antibody Screening
  • 9.2.4. Cross-matching Tests
  • 9.2.5. HLA Typing
• 9.3. Market Analysis, Insights and Forecast - By Techniques
  • 9.3.1. Serology Tests
  • 9.3.2. Molecular Tests
• 9.4. Market Analysis, Insights and Forecast - By End-user
  • 9.4.1. Hospital-based Laboratories
  • 9.4.2. Independent Laboratories & Blood Banks
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Blood Group Typing Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Instruments
  • 10.1.2. Reagents & Kits
• 10.2. Market Analysis, Insights and Forecast - By Test Type
  • 10.2.1. ABO Tests
  • 10.2.2. Antigen Typing
  • 10.2.3. Antibody Screening
  • 10.2.4. Cross-matching Tests
  • 10.2.5. HLA Typing
• 10.3. Market Analysis, Insights and Forecast - By Techniques
  • 10.3.1. Serology Tests
  • 10.3.2. Molecular Tests
• 10.4. Market Analysis, Insights and Forecast - By End-user
  • 10.4.1. Hospital-based Laboratories
  • 10.4.2. Independent Laboratories & Blood Banks
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Quotient Limited
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. CareDx Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Agena Bioscience, Inc. (Mesa Laboratories, Inc.)
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. DIAGAST
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Illumina, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Grifols, S.A.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Immucor, Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Bio-Rad Laboratories, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Thermo Fisher Scientific Inc.
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Merck KGaA
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. QIAGEN
    • 11.2.11.1. Overview
    • 11.2.11.2. Products & Services
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)
  • 11.2.12. Beckman Coulter, Inc. (Danaher)
    • 11.2.12.1. Overview
    • 11.2.12.2. Products & Services
    • 11.2.12.3. SWOT Analysis
    • 11.2.12.4. Recent Developments
    • 11.2.12.5. Strategies
    • 11.2.12.6. Financials (Based on Availability)
  • 11.2.13. QuidelOrtho Corporation
    • 11.2.13.1. Overview
    • 11.2.13.2. Products & Services
    • 11.2.13.3. SWOT Analysis
    • 11.2.13.4. Recent Developments
    • 11.2.13.5. Strategies
    • 11.2.13.6. Financials (Based on Availability)